NCT04253561 2026-03-16
IPATHER
SOLTI Breast Cancer Research Group
Phase 1 Completed
Clinical Trials
9 trialsNCT03959891 2025-09-29
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT05332561 2025-03-20
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
German Cancer Research Center
Phase 2 Recruiting
NCT05498896 2025-03-10
BARBICAN
Queen Mary University of London
Phase 2 Active not recruiting
NCT04464174 2024-07-26
PATHFINDER
MedSIR
Phase 2 Completed
NCT03395899 2024-06-18
ECLIPSE
Queen Mary University of London
Phase 2 Completed
NCT03853707 2024-02-20
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT04920708 2023-10-27
FAIM
Royal Marsden NHS Foundation Trust
Phase 2 Recruiting
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown